RE:RE:Good news....amyloids and tau many have wondered what a small partnership may be worth.. at least with PD or ALS or our Tau... this might give us some idea on the going price right now...\
For rights to the experimental tau drug, Biogen will pay Ionis $45 million up front, up to $155 million based on whether the therapy hits certain milestones, and royalties from any sales for the experimental treatment, which is in a Phase 1 clinical study for patients with mild Alzheimer’s. Under the deal, Ionis will handle the Phase 1 testing, which started in 2017, and a one-year extension study that began this year. Biogen will handle all subsequent studies and further development.